title: Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management.
abstract: The effective management of validated ligand-binding assays used for PK, PD and immunogenicity assessments of biotherapeutics is vital to ensuring robust and consistent assay performance throughout the lifetime of the method. The structural integrity and functional quality of critical reagents is often linked to ligand-binding assay performance; therefore, physicochemical and biophysical characterization coupled with assessment of assay performance can enable the highest degree of reagent quality. The implementation of a systematic characterization process for monitoring critical reagent attributes, utilizing detailed analytical techniques such as LC-MS, can expedite assay troubleshooting and identify deleterious trends. In addition, this minimizes the potential for costly delays in drug development due to reagent instability or batch-to-batch variability. This article provides our perspectives on a proactive critical reagent QC process. Case studies highlight the analytical techniques used to identify chemical and molecular factors and the interdependencies that can contribute to protein heterogeneity and integrity.
authors: Biologics Clinical Pharmacology, Biotechnology Center of Excellence, Janssen R&D, LLC, Radnor, PA 19087, USA. bgeist@its.jnj.com
authors: Brian J
authors: BJ
authors: Geist
authors: Adrienne Clements
authors: AC
authors: Egan
authors: Tong-Yuan
authors: TY
authors: Yang
authors: Yuxin
authors: Y
authors: Dong
authors: Gopi
authors: G
authors: Shankar
mesh_terms: D006801:Humans; D007202:Indicators and Reagents / Q000737:chemistry*; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000097:blood; D011506:Proteins / Q000737:chemistry*; D011786:Quality Control; D013329:Structure-Activity Relationship
chemical_list: D007202:Indicators and Reagents; D008024:Ligands; D004364:Pharmaceutical Preparations; D011506:Proteins